Bayer's Cardiology Push Gains Momentum as Kerendia Sales Surge and a Diagnostic Bet Shows Promise

Bayer showcases Kerendia data and REVEAL tracer results at ESC, while Q2 2026 revenue rises 2.2% and shares gain 74% year-over-year.

The European Society of Cardiology congress in Munich has given Bayer a platform to showcase two distinct pillars of its cardiovascular strategy — one already generating commercial returns, the other still seeking regulatory validation. The company presented a subgroup analysis of its Phase-III FIND-CKD trial for finerenone, marketed as Kerendia, alongside data from a separate diagnostic study that could eventually expand its cardiology footprint.

The timing is propitious. Kerendia has emerged as one of the most dynamic growth assets in Bayer's pharma portfolio, with first-half 2026 sales jumping 75 percent year-on-year to EUR 603 million. The new clinical evidence, which shows the drug slows kidney function decline in patients with hypertensive nephropathy and reduces the combined risk of renal and cardiovascular events, could reinforce prescribing habits and extend the product's momentum beyond the current year. A dedicated approval for non-diabetic chronic kidney disease has not yet been secured, however.

A Diagnostic Complement Takes Shape

Alongside the Kerendia analysis, Bayer presented results from the Phase-III REVEAL study evaluating the PET radiotracer iodine-124 evuzamitide as a diagnostic tool for cardiac amyloidosis, a condition notoriously difficult to identify. In a trial involving 170 patients with suspected disease, the tracer achieved 94 percent sensitivity and 86 percent specificity in a majority-reader assessment. Sensitivity climbed to 96 percent for ATTR amyloidosis and 95 percent for the AL variant. Treatment-emergent adverse events were reported in 32.4 percent of participants. The findings earned a late-breaker slot on the congress program, a marker of their perceived significance among cardiologists.

Should the sensitivity figures hold up in broader clinical use, the diagnostic could become a supplementary revenue stream within Bayer's cardiology portfolio — though that remains a prospective scenario rather than a near-term certainty.

Operating Recovery Provides the Backdrop

The pharma updates land at a moment when the group's broader financial trajectory is stabilising. Second-quarter 2026 group revenue rose 2.2 percent on a currency-adjusted basis to EUR 10.872 billion, while adjusted EBITDA advanced 1.9 percent to EUR 2.144 billion. Bayer swung to a net profit of EUR 219 million, reversing a EUR 199 million loss in the year-earlier period. Crop Science delivered the strongest contribution, with adjusted earnings up 30.2 percent on higher revenues and lower manufacturing costs.

Management reaffirmed its full-year guidance, projecting adjusted EBITDA between EUR 9.6 billion and EUR 10.1 billion and core earnings per share in a range of EUR 4.30 to EUR 4.90. The company also trimmed its net financial debt forecast to EUR 29-30 billion from a prior EUR 32-33 billion, reflecting the anticipated capital injection from Apollo, which is expected to close in the third quarter of 2026.

Share Price Tracks the Turnaround

The equity has mirrored this operational improvement over the past year. At Friday's close, Bayer shares stood at EUR 48.66, up 74 percent from twelve months earlier and 31 percent higher since the start of the year. The stock sits roughly 9.7 percent below its 52-week high of EUR 53.86, reached in early July, while trading comfortably above its 200-day moving average of EUR 41.29. The more granular moves around the congress itself were muted — the shares rose 0.4 percent on Friday and 1.4 percent over the preceding seven sessions — suggesting investors are weighing pipeline progress against the unresolved glyphosate litigation.

That legal overhang remains the principal drag on sentiment. A proposed class settlement of up to USD 7.25 billion is scheduled for final court approval in Missouri on September 14. The distance from the stock's November low — roughly 89 percent — underscores how far the recovery has travelled, yet the glyphosate question continues to cap valuations.

The Kerendia data, combined with the diagnostic promise of REVEAL, bolsters the argument that Bayer can build a credible second growth engine in pharma alongside Crop Science, even as the legal legacy is gradually worked through. Whether that narrative translates into sustained share-price gains will depend on converting clinical wins into commercial results in the quarters ahead.